
Global mRNA Cancer Vaccines and Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
According to APO Research, The global mRNA Cancer Vaccines and Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for mRNA Cancer Vaccines and Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for mRNA Cancer Vaccines and Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for mRNA Cancer Vaccines and Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for mRNA Cancer Vaccines and Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of mRNA Cancer Vaccines and Therapeutics include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA and Ethris, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for mRNA Cancer Vaccines and Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of mRNA Cancer Vaccines and Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for mRNA Cancer Vaccines and Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Cancer Vaccines and Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global mRNA Cancer Vaccines and Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for mRNA Cancer Vaccines and Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
mRNA Cancer Vaccines and Therapeutics Segment by Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
mRNA Cancer Vaccines and Therapeutics Segment by Type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
mRNA Cancer Vaccines and Therapeutics Segment by Application
Infectious Disease
Cancer
Others
mRNA Cancer Vaccines and Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Cancer Vaccines and Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Cancer Vaccines and Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Cancer Vaccines and Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of mRNA Cancer Vaccines and Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Cancer Vaccines and Therapeutics industry.
Chapter 3: Detailed analysis of mRNA Cancer Vaccines and Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Cancer Vaccines and Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
According to APO Research, The global mRNA Cancer Vaccines and Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for mRNA Cancer Vaccines and Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for mRNA Cancer Vaccines and Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for mRNA Cancer Vaccines and Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for mRNA Cancer Vaccines and Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of mRNA Cancer Vaccines and Therapeutics include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA and Ethris, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for mRNA Cancer Vaccines and Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of mRNA Cancer Vaccines and Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for mRNA Cancer Vaccines and Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Cancer Vaccines and Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global mRNA Cancer Vaccines and Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for mRNA Cancer Vaccines and Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
mRNA Cancer Vaccines and Therapeutics Segment by Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
mRNA Cancer Vaccines and Therapeutics Segment by Type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
mRNA Cancer Vaccines and Therapeutics Segment by Application
Infectious Disease
Cancer
Others
mRNA Cancer Vaccines and Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Cancer Vaccines and Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Cancer Vaccines and Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Cancer Vaccines and Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of mRNA Cancer Vaccines and Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Cancer Vaccines and Therapeutics industry.
Chapter 3: Detailed analysis of mRNA Cancer Vaccines and Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Cancer Vaccines and Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
199 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
- 1.2.2 Adeno Carcinomas
- 1.2.3 Mucinous Carcinomas
- 1.2.4 Adenosquamous Carcinomas
- 1.3 Market Analysis by Application
- 1.3.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
- 1.3.2 Infectious Disease
- 1.3.3 Cancer
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global mRNA Cancer Vaccines and Therapeutics Growth Trends by Region
- 1.5.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
- 1.5.2 mRNA Cancer Vaccines and Therapeutics Market Size by Region (2020-2025)
- 1.5.3 mRNA Cancer Vaccines and Therapeutics Market Size by Region (2026-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
- 2 Global mRNA Cancer Vaccines and Therapeutics Market Dynamics
- 2.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
- 2.2 mRNA Cancer Vaccines and Therapeutics Industry Drivers
- 2.3 mRNA Cancer Vaccines and Therapeutics Industry Opportunities and Challenges
- 2.4 mRNA Cancer Vaccines and Therapeutics Industry Restraints
- 3 Competitive Landscape by Company
- 3.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (2020-2025)
- 3.2 Global mRNA Cancer Vaccines and Therapeutics Players Revenue Ranking, 2023 VS 2024 VS 2025
- 3.3 Global mRNA Cancer Vaccines and Therapeutics Key Company Head office and Area Served
- 3.4 Global mRNA Cancer Vaccines and Therapeutics Company, Product Type & Application
- 3.5 Global mRNA Cancer Vaccines and Therapeutics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global mRNA Cancer Vaccines and Therapeutics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 mRNA Cancer Vaccines and Therapeutics Players Market Share by Revenue in 2024
- 3.6.3 2024 mRNA Cancer Vaccines and Therapeutics Tier 1, Tier 2, and Tier 3
- 4 mRNA Cancer Vaccines and Therapeutics Market by Type
- 4.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Type (2020 VS 2024 VS 2031)
- 4.2 Global mRNA Cancer Vaccines and Therapeutics Market Size by Type (2020-2031)
- 4.3 Global mRNA Cancer Vaccines and Therapeutics Market Size Share by Type (2020-2031)
- 5 mRNA Cancer Vaccines and Therapeutics Market by Application
- 5.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Application (2020 VS 2024 VS 2031)
- 5.2 Global mRNA Cancer Vaccines and Therapeutics Market Size by Application (2020-2031)
- 5.3 Global mRNA Cancer Vaccines and Therapeutics Market Size Share by Application (2020-2031)
- 6 Company Profiles
- 6.1 Moderna Therapeutics
- 6.1.1 Moderna Therapeutics Comapny Information
- 6.1.2 Moderna Therapeutics Business Overview
- 6.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.1.5 Moderna Therapeutics Recent Developments
- 6.2 CureVac
- 6.2.1 CureVac Comapny Information
- 6.2.2 CureVac Business Overview
- 6.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.2.5 CureVac Recent Developments
- 6.3 Translate Bio
- 6.3.1 Translate Bio Comapny Information
- 6.3.2 Translate Bio Business Overview
- 6.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.3.5 Translate Bio Recent Developments
- 6.4 BioNTech
- 6.4.1 BioNTech Comapny Information
- 6.4.2 BioNTech Business Overview
- 6.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.4.5 BioNTech Recent Developments
- 6.5 Sangamo Therapeutics
- 6.5.1 Sangamo Therapeutics Comapny Information
- 6.5.2 Sangamo Therapeutics Business Overview
- 6.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.5.5 Sangamo Therapeutics Recent Developments
- 6.6 Argos Therapeutics
- 6.6.1 Argos Therapeutics Comapny Information
- 6.6.2 Argos Therapeutics Business Overview
- 6.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.6.5 Argos Therapeutics Recent Developments
- 6.7 In-Cell-Art
- 6.7.1 In-Cell-Art Comapny Information
- 6.7.2 In-Cell-Art Business Overview
- 6.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.7.5 In-Cell-Art Recent Developments
- 6.8 eTheRNA
- 6.8.1 eTheRNA Comapny Information
- 6.8.2 eTheRNA Business Overview
- 6.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.8.5 eTheRNA Recent Developments
- 6.9 Ethris
- 6.9.1 Ethris Comapny Information
- 6.9.2 Ethris Business Overview
- 6.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.9.5 Ethris Recent Developments
- 6.10 Tiba Biotechnology
- 6.10.1 Tiba Biotechnology Comapny Information
- 6.10.2 Tiba Biotechnology Business Overview
- 6.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2020-2025)
- 6.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.10.5 Tiba Biotechnology Recent Developments
- 7 North America
- 7.1 North America mRNA Cancer Vaccines and Therapeutics Market Size (2020-2031)
- 7.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 7.2.1 North America mRNA Cancer Vaccines and Therapeutics Market Size by Type (2020-2025)
- 7.2.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Type (2026-2031)
- 7.2.3 North America mRNA Cancer Vaccines and Therapeutics Market Share by Type (2020-2031)
- 7.3 North America mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 7.3.1 North America mRNA Cancer Vaccines and Therapeutics Market Size by Application (2020-2025)
- 7.3.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Application (2026-2031)
- 7.3.3 North America mRNA Cancer Vaccines and Therapeutics Market Share by Application (2020-2031)
- 7.4 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country
- 7.4.1 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2020 VS 2024 VS 2031)
- 7.4.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2020-2025)
- 7.4.3 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2026-2031)
- 7.4.4 North America mRNA Cancer Vaccines and Therapeutics Market Share by Country (2020-2031)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
- 8 Europe
- 8.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size (2020-2031)
- 8.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 8.2.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Type (2020-2025)
- 8.2.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Type (2026-2031)
- 8.2.3 Europe mRNA Cancer Vaccines and Therapeutics Market Share by Type (2020-2031)
- 8.3 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 8.3.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Application (2020-2025)
- 8.3.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Application (2026-2031)
- 8.3.3 Europe mRNA Cancer Vaccines and Therapeutics Market Share by Application (2020-2031)
- 8.4 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country
- 8.4.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2020 VS 2024 VS 2031)
- 8.4.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2020-2025)
- 8.4.3 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2026-2031)
- 8.4.4 Europe mRNA Cancer Vaccines and Therapeutics Market Share by Country (2020-2031)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
- 9 China
- 9.1 China mRNA Cancer Vaccines and Therapeutics Market Size (2020-2031)
- 9.2 China mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 9.2.1 China mRNA Cancer Vaccines and Therapeutics Market Size by Type (2020-2025)
- 9.2.2 China mRNA Cancer Vaccines and Therapeutics Market Size by Type (2026-2031)
- 9.2.3 China mRNA Cancer Vaccines and Therapeutics Market Share by Type (2020-2031)
- 9.3 China mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 9.3.1 China mRNA Cancer Vaccines and Therapeutics Market Size by Application (2020-2025)
- 9.3.2 China mRNA Cancer Vaccines and Therapeutics Market Size by Application (2026-2031)
- 9.3.3 China mRNA Cancer Vaccines and Therapeutics Market Share by Application (2020-2031)
- 10 Asia (Excluding China)
- 10.1 Asia mRNA Cancer Vaccines and Therapeutics Market Size (2020-2031)
- 10.2 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 10.2.1 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Type (2020-2025)
- 10.2.2 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Type (2026-2031)
- 10.2.3 Asia mRNA Cancer Vaccines and Therapeutics Market Share by Type (2020-2031)
- 10.3 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 10.3.1 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Application (2020-2025)
- 10.3.2 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Application (2026-2031)
- 10.3.3 Asia mRNA Cancer Vaccines and Therapeutics Market Share by Application (2020-2031)
- 10.4 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Country
- 10.4.1 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Country (2020 VS 2024 VS 2031)
- 10.4.2 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Country (2020-2025)
- 10.4.3 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Country (2026-2031)
- 10.4.4 Asia mRNA Cancer Vaccines and Therapeutics Market Share by Country (2020-2031)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
- 11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size (2020-2031)
- 11.2 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 11.2.1 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Type (2020-2025)
- 11.2.2 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Type (2026-2031)
- 11.2.3 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Share by Type (2020-2031)
- 11.3 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 11.3.1 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Application (2020-2025)
- 11.3.2 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Application (2026-2031)
- 11.3.3 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Share by Application (2020-2031)
- 11.4 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country
- 11.4.1 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2020 VS 2024 VS 2031)
- 11.4.2 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2020-2025)
- 11.4.3 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2026-2031)
- 11.4.4 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Share by Country (2020-2031)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.